Literature DB >> 32007568

Unmet needs of children with peanut allergy: Aligning the risks and the evidence.

Edmond S Chan1, Chitra Dinakar2, Erika Gonzales-Reyes3, Todd D Green4, Ruchi Gupta5, Douglas Jones6, Julie Wang7, Tonya Winders8, Matthew Greenhawt9.   

Abstract

BACKGROUND: Peanut allergy is a potentially severe and lifelong allergy, with few effective treatments or preventive measures.
OBJECTIVE: To convene an expert panel of allergists, pediatricians, and advocates to discuss and highlight unmet needs in the prevention and management of peanut allergies.
METHODS: Literature searches of PubMed were performed. The panel evaluated published data on the prevention of peanut allergy, treatment of existing peanut allergy, and management of reactions after unintentional peanut exposures.
RESULTS: The following key unmet needs in the prevention and management of peanut allergy were identified: (1) enhancing and optimizing implementation of early peanut introduction as a means of preventing the development of peanut allergy, (2) developing knowledge translation strategies regarding the safety and efficacy data for current and emerging immunotherapies for peanut-allergic children to support their use in clinical practice, and (3) promoting understanding of true exposure risk in allergic individuals and ensuring access to epinephrine for unintentional exposures that provoke severe reactions. Practitioners should help educate caregivers about the actual risks associated with peanut allergy and its prevention and management so that treatment decisions can be evidence based rather than fear based. Support tools are needed to help address caregiver goals, expectations, and psychological barriers, as well as identify facilitators for prevention and treatment strategies.
CONCLUSION: There are significant unmet needs in our understanding of peanut allergy; addressing these needs will help to enhance understanding of how to most effectively prevent and treat peanut allergy, as well as educate the food-allergic and nonallergic community regarding current evidence-based practices.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32007568     DOI: 10.1016/j.anai.2020.01.016

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  4 in total

1.  Weighing the benefits and risks of oral immunotherapy in clinical practice.

Authors:  Aikaterini Anagnostou
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

Review 2.  IgE-Mediated Peanut Allergy: Current and Novel Predictive Biomarkers for Clinical Phenotypes Using Multi-Omics Approaches.

Authors:  Rebecca Czolk; Julia Klueber; Martin Sørensen; Paul Wilmes; Françoise Codreanu-Morel; Per Stahl Skov; Christiane Hilger; Carsten Bindslev-Jensen; Markus Ollert; Annette Kuehn
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

Review 3.  A Practical, Stepwise Approach to Peanut Oral Immunotherapy in Clinical Practice: Benefits and Risks.

Authors:  Aikaterini Anagnostou
Journal:  J Asthma Allergy       Date:  2021-03-25

4.  Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond.

Authors:  Gilbert T Chua; Edmond S Chan; Lianne Soller; Victoria E Cook; Timothy K Vander Leek; Raymond Mak
Journal:  Front Allergy       Date:  2021-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.